Log in

M&ABusinessLine

Piramal Pharma to acquire remaining 26% stake in Yapan Bio

Positive+33

GreyOak summary

Piramal Pharma Limited announced it will acquire the remaining 26% equity stake in Yapan Bio Private Limited via an exercised call option. This transaction will increase Piramal's shareholding from 74% to 100%, making Yapan a wholly owned subsidiary. Final terms, including consideration and the effective transfer date, are yet to be finalized.

What it affects

Source

Read the original at BusinessLine

More Piramal Pharma news

No other recent stories about Piramal Pharma.

All Piramal Pharma news →

We use cookies

Essential cookies keep GreyOak secure and functional. Optional cookies help improve your experience and platform performance. You can update your preferences anytime.

Cookie Policy